{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:49Z","timestamp":1793242309107,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["-5169"],"award-info":[{"award-number":["-5169"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.10.001","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:21:45Z","timestamp":1697048505000},"page":"e21-e32.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-9482","authenticated-orcid":false,"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5915-5523","authenticated-orcid":false,"given":"Mingchen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-9897","authenticated-orcid":false,"given":"Kristina S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.10.001_bib0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2015.12.018","article-title":"Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: cutaneous T-cell lymphomas","volume":"99","author":"Zinzani","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.clml.2023.10.001_bib0002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/17474086.2020.1717945","article-title":"The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review","volume":"13","author":"Dalal","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.clml.2023.10.001_bib0003","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-cell lymphoma in the US from 2000 to 2018: a SEER population data analysis","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clml.2023.10.001_bib0004","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"10094","key":"10.1016\/j.clml.2023.10.001_bib0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clml.2023.10.001_bib0006","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11532190-000000000-00000","article-title":"Current and emerging treatment strategies for cutaneous T-cell lymphoma","volume":"70","author":"Lansigan","year":"2010","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.clml.2023.10.001_bib0007","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.17117","article-title":"The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma","volume":"192","author":"Scarisbrick","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.10.001_bib0008","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3389\/fonc.2020.00765","article-title":"Update on biology of cutaneous T-cell lymphoma","volume":"10","author":"Phyo","year":"2020","journal-title":"Front Oncol"},{"issue":"32","key":"10.1016\/j.clml.2023.10.001_bib0009","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.001_bib0010","unstructured":"FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma. Accessed: March 27, 2023, 2023. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brentuximab-vedotin-treatment-adult-patients-primary-cutaneous-anaplastic-large-cell."},{"issue":"32","key":"10.1016\/j.clml.2023.10.001_bib0011","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.001_sbref0012","series-title":"Prescribing information","year":"2022"},{"issue":"23","key":"10.1016\/j.clml.2023.10.001_bib0013","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.clml.2023.10.001_bib0014","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.10.001_bib0015","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.clml.2023.10.001_bib0016","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.001_bib0017","unstructured":"The National Academies Collection: Reports funded by the Institutes of Health. In: Bibbins-Domingo K, Helman A, eds. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington, DC: National Academies Press (US); 2022."},{"key":"10.1016\/j.clml.2023.10.001_bib0018","unstructured":"Riskin D. Real-world evidence studies can enhance diversity and equity in clinical research. Accessed November 18, 2022. Available at: https:\/\/www.appliedclinicaltrialsonline.com\/view\/real-world-evidence-studies-can-enhance-diversity-and-equity-in-clinical-research."},{"issue":"1","key":"10.1016\/j.clml.2023.10.001_bib0019","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/cancers14010145","article-title":"Contemporary treatment patterns and response in relapsed\/refractory cutaneous T-cell lymphoma (CTCL) across five European countries","volume":"14","author":"Assaf","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.clml.2023.10.001_bib0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/09546634.2018.1466026","article-title":"Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis","volume":"29","author":"Tsang","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.clml.2023.10.001_bib0021","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bjd.18535","article-title":"Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma","volume":"182","author":"Engelina","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.clml.2023.10.001_bib0022","first-page":"383","article-title":"Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma","volume":"19","author":"Stranzenbach","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clml.2023.10.001_bib0023","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.clml.2023.10.001_bib0024","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:57Z","timestamp":1761871377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023021468"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}